Volibris (ambrisentan) - Important Safety Information from GlaxoSmithKline as approved by the Irish Medicines Board
24 July 2012
Important Safety Information from GlaxoSmithKline, Volibirs (ambrisentan) must not be used in patients with Idiopathic Pulmonary Fibrosis (IPF).
Important safety information - Volibiris (ambrisentan)